Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TGF-β in tumor development and progression: mechanisms and therapeutics. | Mol Biomed | 2026 | 41615651 | PubTator, text mining | PubMed |
| Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells. | J Immunother Cancer | 2026 | 41611243 | PubTator, text mining | PubMed |
| A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol. | PLoS One | 2026 | 41610103 | PubTator, text mining | PubMed |
| Metastatic organotropism in peritoneal metastasis: Paget's hypothesis revisited. | Clin Exp Med | 2026 | 41609906 | PubTator, text mining | PubMed |
| Computational Modeling of Cellular Influence Delineates Functionally Relevant and Distinct Cellular Neighborhoods in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. | Cancer Immunol Res | 2026 | 41592755 | PubTator, text mining | PubMed |
| Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer. | Br J Cancer | 2026 | 41588173 | PubTator, text mining | PubMed |
| Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications. | Signal Transduct Target Ther | 2026 | 41582215 | PubTator, text mining | PubMed |
| IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma. | Cancer Cell | 2026 | 41576930 | PubTator, text mining | PubMed |
| Methionine restriction for cancer therapy: From preclinical studies to clinical trials. | Cancer Pathog Ther | 2026 | 41550357 | PubTator, text mining | PubMed |
| Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review). | Oncol Rep | 2026 | 41543151 | PubTator, text mining | PubMed |
| Hyperglycemia drives lmmune evasion in colorectal cancer through VISTA stabilization. | Cell Commun Signal | 2026 | 41501851 | PubTator, text mining | PubMed |
| Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications. | J Biomed Sci | 2026 | 41486149 | PubTator, text mining | PubMed |
| Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer. | Eur Urol Oncol | 2026 | 41475987 | PubTator, text mining | PubMed |
| Matrix Type Influences the Levels of Soluble Immune Checkpoints. | J Clin Lab Anal | 2026 | 41460822 | PubTator, text mining | PubMed |
| Machine learning-guided discovery and molecular dynamics simulation of VISTA-targeted immunotherapeutics for cancer immunotherapy. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 41452360 | PubTator, text mining | PubMed |
| On the same side: VISTA and its ligands interact in cis on the cell surface. | Protein Sci | 2026 | 41427660 | PubTator, text mining | PubMed |
| Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers. | J Cell Immunol | 2025 | 41799379 | PubTator, text mining | PubMed |
| Immune activation and microenvironmental crosstalk in hairy cell leukemia. | Front Immunol | 2025 | 41726184 | PubTator, text mining | PubMed |
| Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis. | Front Immunol | 2025 | 41660625 | PubTator, text mining | PubMed |
| Keratinocyte VISTA attenuates UV light-induced skin injury by suppressing cutaneous type I interferon (IFN-I) response. | bioRxiv | 2025 | 41573829 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=5